Mohamad Alabrash, MD
Critical Care Medicine · White Marsh, MDNPI 1629174966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 51.2% of the total.
Across 82 payments — averaging $47.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Dexcom, Inc.$421
- Abbott$405
- Novo Nordisk$284
- Novartis$276
- Lilly USA, LLC$171
- plus $328 from 7 others
What the payments were for
- Food & beverage$3,83699%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $1,975 |
| Dexcom, Inc. | 3 | $421 |
| Abbott | 6 | $405 |
| Novo Nordisk | 17 | $284 |
| Novartis | 6 | $276 |
| Lilly USA, LLC | 8 | $171 |
| E.r. Squibb & Sons, L.L.C. | 4 | $107 |
| Boehringer Ingelheim | 4 | $88 |
| Merck | 4 | $59 |
| AbbVie(2 entities) | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Mylan Specialty L.p. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$854
- BREZTRI$479
- FREESTYLE LIBRE 3$383
- LOKELMA$353
- DEXCOM G6 TRANSMITTER$281
- ENTRESTO$239
- DEXCOM G7 GSS (161)$140
- DEXCOM STELO GLUCOSE BIOSENSOR$140
How this compares
$3,859 in reported general payments places this provider in the 85th percentile of 231 critical care medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $37,094 |
| TrulicityDulaglutide | 12 | $23,253 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $20,173 |
| MounjaroTirzepatide | 14 | $16,492 |
| FarxigaDapagliflozin Propanediol | 14 | $10,949 |
| Metoprolol Succinate | 134 | $2,545 |
| Roflumilast | 14 | $2,045 |
| Levothyroxine Sodium | 122 | $1,609 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,512 |
| Losartan Potassium | 152 | $1,293 |
| Rosuvastatin Calcium | 71 | $1,115 |
| Gabapentin | 36 | $1,049 |
| Amlodipine Besylate | 139 | $958 |
| Colchicine | 11 | $896 |
| Simvastatin | 64 | $887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $171 | $39,74526 claims |
| Boehringer IngelheimCombivent Respimat | $88 | $20,17324 claims |
| AstraZenecaFarxiga | $1,975 | $10,94914 claims |
| AbbVieSynthroid | $25 | $46412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 critical care medicine providers in Maryland.
Other critical care medicine in White Marsh
- Christopher ChapmanMitchellville$248K
- David Feller KopmanBaltimore$236K
- Elizabeth HuntBaltimore$182K
- Robert BrowningBethesda$73K
- Edward BrittBaltimore$70K
- Lydia Gilbert-McclainBethesda$68K
- Nirav ShahBaltimore$55K
- Steven KellerBaltimore$31K
- Daniel BrodieBethesda$26K
- Nader HabashiBaltimore$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.